A Collaborative Analysis of Individual Participant Data from 19 Prospective Studies Assesses Circulating Vitamin D and Prostate Cancer Risk

Previous prospective studies assessing the relationship between circulating concentrations of vitamin D and prostate cancer risk have shown inconclusive results, particularly for risk of aggressive disease. In this study, we examine the association between prediagnostic concentrations of 25-hydroxyvitamin D [25(OH)D] and 1,25-dihydroxyvitamin D [1,25(OH)D] and the risk of prostate cancer overall and by tumor characteristics. Principal investigators of 19 prospective studies provided individual participant data on circulating 25(OH)D and 1,25(OH)D for up to 13,462 men with incident prostate cancer and 20,261 control participants. ORs for prostate cancer by study-specific fifths of season-standardized vitamin D concentration were estimated using multivariable-adjusted conditional logistic regression. 25(OH)D concentration was positively associated with risk for total prostate cancer (multivariable-adjusted OR comparing highest vs. lowest study-specific fifth was 1.22; 95% confidence interval, 1.13-1.31; trend < 0.001). However, this association varied by disease aggressiveness ( = 0.014); higher circulating 25(OH)D was associated with a higher risk of nonaggressive disease (OR per 80 percentile increase = 1.24, 1.13-1.36) but not with aggressive disease (defined as stage 4, metastases, or prostate cancer death, 0.95, 0.78-1.15). 1,25(OH)D concentration was not associated with risk for prostate cancer overall or by tumor characteristics. The absence of an association of vitamin D with aggressive disease does not support the hypothesis that vitamin D deficiency increases prostate cancer risk. Rather, the association of high circulating 25(OH)D concentration with a higher risk of nonaggressive prostate cancer may be influenced by detection bias. SIGNIFICANCE: This international collaboration comprises the largest prospective study on blood vitamin D and prostate cancer risk and shows no association with aggressive disease but some evidence of a higher risk of nonaggressive disease.

Citing Articles

Cancer prevention: past challenges and future directions.

Seong H, Izutsu R, Osaki M, Okada F Genes Environ. 2025; 47(1):4.

PMID: 40011962 PMC: 11866826. DOI: 10.1186/s41021-025-00326-y.

Vitamin D binding protein genetic isoforms, serum vitamin D, and cancer risk in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.

Weinstein S, Parisi D, Mondul A, Layne T, Huang J, Stolzenberg-Solomon R PLoS One. 2024; 19(12):e0315252.

PMID: 39705237 PMC: 11661580. DOI: 10.1371/journal.pone.0315252.

Intratumoral vitamin D signaling and lethal prostate cancer.

Vaselkiv J, Shui I, Grob S, Ericsson C, Giovannucci I, Peng C Carcinogenesis. 2024; 45(10):735-744.

PMID: 39120256 PMC: 11464699. DOI: 10.1093/carcin/bgae055.

Discordant Health Implications and Molecular Mechanisms of Vitamin D in Clinical and Preclinical Studies of Prostate Cancer: A Critical Appraisal of the Literature Data.

Fendler A, Stephan C, Ralla B, Jung K Int J Mol Sci. 2024; 25(10).

PMID: 38791324 PMC: 11120741. DOI: 10.3390/ijms25105286.

High-dose vitamin D to attenuate bone loss in patients with prostate cancer on androgen deprivation therapy: A phase 2 RCT.

Peppone L, Kleckner A, Fung C, Puzas J, Reschke J, Culakova E Cancer. 2024; 130(14):2538-2551.

PMID: 38520382 PMC: 11214601. DOI: 10.1002/cncr.35275.

References

Price A, Travis R, Appleby P, Albanes D, Barricarte Gurrea A, Bjorge T . Circulating Folate and Vitamin B and Risk of Prostate Cancer: A Collaborative Analysis of Individual Participant Data from Six Cohorts Including 6875 Cases and 8104 Controls. Eur Urol. 2016; 70(6):941-951. PMC: 5094800. DOI: 10.1016/j.eururo.2016.03.029. View

Peng L, J Malloy P, Feldman D . Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol. 2004; 18(5):1109-19. DOI: 10.1210/me.2003-0344. View

Barnett C, Nielson C, Shannon J, Chan J, Shikany J, Bauer D . Serum 25-OH vitamin D levels and risk of developing prostate cancer in older men. Cancer Causes Control. 2010; 21(8):1297-303. PMC: 2903686. DOI: 10.1007/s10552-010-9557-y. View

Schwartz G, Hulka B . Is vitamin D deficiency a risk factor for prostate cancer? (Hypothesis). Anticancer Res. 1990; 10(5A):1307-11. View

Dimitrakopoulou V, Tsilidis K, Haycock P, Dimou N, Al-Dabhani K, Martin R . Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study. BMJ. 2017; 359:j4761. PMC: 5666592. DOI: 10.1136/bmj.j4761. View

Holick M . Vitamin D deficiency. N Engl J Med. 2007; 357(3):266-81. DOI: 10.1056/NEJMra070553. View

Gann P, Ma J, Hennekens C, Hollis B, Haddad J, Stampfer M . Circulating vitamin D metabolites in relation to subsequent development of prostate cancer. Cancer Epidemiol Biomarkers Prev. 1996; 5(2):121-6. View

Ordonez-Mena J, Schottker B, Fedirko V, Jenab M, Olsen A, Halkjaer J . Pre-diagnostic vitamin D concentrations and cancer risks in older individuals: an analysis of cohorts participating in the CHANCES consortium. Eur J Epidemiol. 2015; 31(3):311-23. DOI: 10.1007/s10654-015-0040-7. View

Meng J, Hovey K, Wactawski-Wende J, Andrews C, LaMonte M, Horst R . Intraindividual variation in plasma 25-hydroxyvitamin D measures 5 years apart among postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2012; 21(6):916-24. PMC: 3372646. DOI: 10.1158/1055-9965.EPI-12-0026. View

10.

Fleet J . Molecular actions of vitamin D contributing to cancer prevention. Mol Aspects Med. 2008; 29(6):388-96. PMC: 2613446. DOI: 10.1016/j.mam.2008.07.003. View

11.

Jacobs E, Giuliano A, Martinez M, Hollis B, Reid M, Marshall J . Plasma levels of 25-hydroxyvitamin D, 1,25-dihydroxyvitamin D and the risk of prostate cancer. J Steroid Biochem Mol Biol. 2004; 89-90(1-5):533-7. DOI: 10.1016/j.jsbmb.2004.03.063. View

12.

Li H, Stampfer M, Hollis J, Mucci L, Gaziano J, Hunter D . A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. PLoS Med. 2007; 4(3):e103. PMC: 1831738. DOI: 10.1371/journal.pmed.0040103. View

13.

Corder E, Guess H, Hulka B, Friedman G, Sadler M, Vollmer R . Vitamin D and prostate cancer: a prediagnostic study with stored sera. Cancer Epidemiol Biomarkers Prev. 1993; 2(5):467-72. View

14.

Key T, Appleby P, Allen N, Reeves G . Pooling biomarker data from different studies of disease risk, with a focus on endogenous hormones. Cancer Epidemiol Biomarkers Prev. 2010; 19(4):960-5. PMC: 2875156. DOI: 10.1158/1055-9965.EPI-10-0061. View

15.

Swami S, Krishnan A, Feldman D . Vitamin D metabolism and action in the prostate: implications for health and disease. Mol Cell Endocrinol. 2011; 347(1-2):61-9. PMC: 3189327. DOI: 10.1016/j.mce.2011.05.010. View

16.

Gilbert R, Martin R, Beynon R, Harris R, Savovic J, Zuccolo L . Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control. 2011; 22(3):319-40. DOI: 10.1007/s10552-010-9706-3. View

17.

Nomura A, STEMMERMANN G, Lee J, Kolonel L, Chen T, Turner A . Serum vitamin D metabolite levels and the subsequent development of prostate cancer (Hawaii, United States). Cancer Causes Control. 1998; 9(4):425-32. DOI: 10.1023/a:1008875819232. View

18.

Corder E, Friedman G, Vogelman J, ORENTREICH N . Seasonal variation in vitamin D, vitamin D-binding protein, and dehydroepiandrosterone: risk of prostate cancer in black and white men. Cancer Epidemiol Biomarkers Prev. 1995; 4(6):655-9. View

19.

Schwartz G, Hanchette C . UV, latitude, and spatial trends in prostate cancer mortality: all sunlight is not the same (United States). Cancer Causes Control. 2006; 17(8):1091-101. DOI: 10.1007/s10552-006-0050-6. View

20.

Platz E, Leitzmann M, Hollis B, Willett W, Giovannucci E . Plasma 1,25-dihydroxy- and 25-hydroxyvitamin D and subsequent risk of prostate cancer. Cancer Causes Control. 2004; 15(3):255-65. DOI: 10.1023/B:CACO.0000024245.24880.8a. View